Ardelyx (NASDAQ:ARDX – Free Report) had its target price increased by Citigroup from $13.00 to $14.00 in a research report released on Friday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. ARDX has been the topic of several other research reports. Leerink Partnrs reiterated an outperform rating on shares […]
Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) has been assigned an average rating of “Buy” from the nine analysts that are covering the stock, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages […]
Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) was the recipient of unusually large options trading activity on Friday. Traders bought 18,613 call options on the stock. This is an increase of 219% compared to the typical daily volume of 5,838 call options. Ardelyx Stock Performance NASDAQ ARDX traded up $1.78 during trading on Friday, reaching […]
Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report)’s share price gapped up prior to trading on Friday following a stronger than expected earnings report. The stock had previously closed at $6.79, but opened at $8.36. Ardelyx shares last traded at $8.45, with a volume of 8,785,366 shares trading hands. The biopharmaceutical company reported ($0.11) earnings per […]
Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) CEO Michael Raab sold 30,000 shares of the stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $6.40, for a total value of $192,000.00. Following the completion of the transaction, the chief executive officer now owns 1,310,933 shares […]